EWM
ACHL

Endurance Wealth Management’s Achilles Therapeutics ACHL Stock Holding History

Endurance Wealth Management’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$0 Hold
2,000
– – ﹤0.01% 667
2023
Q1 		$0 Buy
2,000
+1,998
+99,900% +$2.17K ﹤0.01% 667
2022
Q4 		$0 Hold
2
– – ﹤0.01% 666
2022
Q3 		$5K Hold
2
– – ﹤0.01% 522
2022
Q2 		$5K Hold
2
– – ﹤0.01% 535
2022
Q1 		$8K Hold
2
– – ﹤0.01% 542
2021
Q4 		$10K Buy
+2
New +$12 ﹤0.01% 510

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
EdenTree Asset Management London, United Kingdom $332M AUM 16.64% 1-Year Est. Return
FA
Forefront Analytics West Conshohocken, Pennsylvania $110M AUM 18.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Endurance Wealth Management's ACHL Position: Q2 2023 in Review

Endurance Wealth Management held its Achilles Therapeutics (ACHL) position steady in Q2 2023 at 2,000 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #667.

Endurance Wealth Management first reported a position in ACHL in Q4 2021 and has held it in 7 quarters since. The position peaked at $10K in Q4 2021. 18 funds tracked by Wall St. Rank hold ACHL as of Q2 2023.

  • Endurance Wealth Management held 2,000 shares of Achilles Therapeutics worth $0 as of Q2 2023.
  • Endurance Wealth Management left its Achilles Therapeutics share count unchanged in Q2 2023.
  • Achilles Therapeutics made up ﹤0.01% of Endurance Wealth Management's portfolio in Q2 2023, its #667 holding.
  • Endurance Wealth Management first reported a position in Achilles Therapeutics in Q4 2021 and has held it in 7 quarters since.
  • Endurance Wealth Management's Achilles Therapeutics position peaked at $10K in Q4 2021.
  • 18 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q2 2023.

Based on Endurance Wealth Management's 13F filing for Q2 2023, filed 9 Aug 2023.